JP2024520756A5 - - Google Patents
Info
- Publication number
- JP2024520756A5 JP2024520756A5 JP2023575397A JP2023575397A JP2024520756A5 JP 2024520756 A5 JP2024520756 A5 JP 2024520756A5 JP 2023575397 A JP2023575397 A JP 2023575397A JP 2023575397 A JP2023575397 A JP 2023575397A JP 2024520756 A5 JP2024520756 A5 JP 2024520756A5
- Authority
- JP
- Japan
- Prior art keywords
- peg
- pharmaceutical composition
- composition according
- polypeptide
- lnp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163197881P | 2021-06-07 | 2021-06-07 | |
| US63/197,881 | 2021-06-07 | ||
| PCT/US2022/032510 WO2022261101A1 (en) | 2021-06-07 | 2022-06-07 | Apoe and apob modified lipid nanoparticle compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520756A JP2024520756A (ja) | 2024-05-24 |
| JP2024520756A5 true JP2024520756A5 (cg-RX-API-DMAC7.html) | 2025-06-17 |
Family
ID=84426303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575397A Pending JP2024520756A (ja) | 2021-06-07 | 2022-06-07 | ApoE及びApoB修飾脂質ナノ粒子組成物及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240299580A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4351533A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024520756A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240019244A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117897143A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022288618A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3221454A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308928A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022261101A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4626402A1 (en) | 2022-12-01 | 2025-10-08 | Generation Bio Co. | Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers |
| US20260207525A1 (en) | 2022-12-01 | 2026-07-23 | Generation Bio Co. | Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses |
| JP2025541726A (ja) | 2022-12-01 | 2025-12-23 | ジェネレーション バイオ カンパニー | 細胞標的化のためのステルス脂質ナノ粒子組成物 |
| AU2023406321A1 (en) | 2022-12-01 | 2025-05-29 | Generation Bio Co. | Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same |
| EP4648754A1 (en) * | 2023-01-09 | 2025-11-19 | Northmirs, Inc. | Microrna-based particle for the treatment of dysregulated immune response |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| JP2026512425A (ja) | 2023-03-30 | 2026-04-16 | オーエスイー・イミュノセラピューティクス | 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用 |
| EP4704855A1 (en) * | 2023-04-26 | 2026-03-11 | Saliogen Therapeutics, Inc. | Lipid nanoparticle (lnp) formulations |
| IT202300015291A1 (it) * | 2023-07-20 | 2025-01-20 | Fond Riccardo Terzi E Silvio Albini | Sistema di rilascio comprendente nanoparticelle lipidiche o polimeriche comprendenti ormoni tiroidei |
| WO2025052180A2 (en) | 2023-09-07 | 2025-03-13 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2025230906A1 (en) * | 2024-04-29 | 2025-11-06 | Saliogen Therapeutics, Inc. | Lipid nanoparticle (lnp) formulations |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| CN118453517B (zh) * | 2024-07-15 | 2024-10-08 | 杭州珞米医疗科技有限公司 | 一种靶向结合ldlr的组合物及其应用 |
| WO2026052871A1 (en) * | 2024-09-09 | 2026-03-12 | Re3B Therapeutics Ug (I.G.) | Serum-protein coated fusogenic lipid particles for targeted drug delivery |
| WO2026064512A1 (en) | 2024-09-18 | 2026-03-26 | Generation Bio Co. | Polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006029125A2 (en) * | 2004-09-07 | 2006-03-16 | Kos Life Sciences, Inc. | Methods and compositions for treating hypercholesterolemia |
| US20090131358A1 (en) * | 2007-11-15 | 2009-05-21 | Alcon Research, Ltd. | LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY |
| EP3672602A1 (en) * | 2017-08-22 | 2020-07-01 | Rubius Therapeutics, Inc. | Lipid nanoparticle methods and compositions for producing engineered erythroid cells |
| AU2020232790A1 (en) * | 2019-03-06 | 2021-09-16 | Generation Bio Co. | Non-active lipid nanoparticles with non-viral, capsid free DNA |
| CN114929205B (zh) * | 2019-09-06 | 2024-09-03 | 世代生物公司 | 包括末端封闭式dna和可切割脂质的脂质纳米颗粒组合物及其使用方法 |
| US20230365995A1 (en) * | 2020-10-07 | 2023-11-16 | Precision Biosciences, Inc. | Lipid nanoparticle compositions |
-
2022
- 2022-06-07 WO PCT/US2022/032510 patent/WO2022261101A1/en not_active Ceased
- 2022-06-07 KR KR1020247000414A patent/KR20240019244A/ko active Pending
- 2022-06-07 CN CN202280053409.2A patent/CN117897143A/zh active Pending
- 2022-06-07 JP JP2023575397A patent/JP2024520756A/ja active Pending
- 2022-06-07 CA CA3221454A patent/CA3221454A1/en active Pending
- 2022-06-07 IL IL308928A patent/IL308928A/en unknown
- 2022-06-07 US US18/567,412 patent/US20240299580A1/en active Pending
- 2022-06-07 EP EP22820897.1A patent/EP4351533A4/en active Pending
- 2022-06-07 AU AU2022288618A patent/AU2022288618A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sun et al. | Structure and function of cationic and ionizable lipids for nucleic acid delivery | |
| US12252470B2 (en) | Lipids and nanoparticle compositions thereof | |
| JP2023534043A5 (cg-RX-API-DMAC7.html) | ||
| AU2020423601B2 (en) | Lipid nanoparticles for in-vivo drug delivery, and uses thereof | |
| US20230320993A1 (en) | Methods for encapsulating polynucleotides into reduced sizes of lipid nanoparticles and novel formulation thereof | |
| US20220370357A1 (en) | Ionizable lipids and nanoparticle compositions thereof | |
| US12263228B2 (en) | Lipids and compositions thereof | |
| JP2024520756A (ja) | ApoE及びApoB修飾脂質ナノ粒子組成物及びその使用 | |
| US20240293574A1 (en) | Cationic lipids and compositions thereof | |
| JP2011529912A (ja) | 核酸送達システム用のナノ粒子組成物 | |
| JP2024517644A5 (cg-RX-API-DMAC7.html) | ||
| JP2024522692A5 (cg-RX-API-DMAC7.html) | ||
| US20230181764A1 (en) | Novel lipids and nanoparticle compositions thereof | |
| JP2024529343A5 (cg-RX-API-DMAC7.html) | ||
| JP2025541727A (ja) | 新規のポリグリセロールコンジュゲート脂質及びそれを含む脂質ナノ粒子組成物 | |
| Koynova et al. | Recent patents in cationic lipid carriers for delivery of nucleic acids | |
| Sorgi et al. | Drug delivery applications | |
| KR20250158420A (ko) | 신규 이온화지질 및 이를 포함하는 지질나노입자 | |
| NICOLAUª et al. | ªCBR Laboratories and Harvard Medical School, Boston, MA 02135, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA and CPMCRI, San Francisco, CA 94115, USA | |
| BHATTACHARYAT et al. | Cationic liposome-DNA complexes in |